Ordelheide Anna-Maria, Hrabě de Angelis Martin, Häring Hans-Ulrich, Staiger Harald
Institute for Diabetes Research & Metabolic Diseases of the Helmholtz Centre Munich at the Eberhard Karls University Tübingen, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Pharmacogenomics. 2018 Apr;19(6):577-587. doi: 10.2217/pgs-2017-0195. Epub 2018 Mar 27.
Type 2 diabetes prevalence is still on the rise worldwide. Antidiabetic drugs are widely prescribed to patients with Type 2 diabetes. Most patients start with metformin which is mostly well tolerated. However, a high percentage of patients fail to achieve glycemic control. The effectiveness of metformin as well as most other antidiabetic drugs depends among other factors on interindividual genetic differences that are up to now ignored in the treatment of Type 2 diabetes. Interestingly, many genes influencing the effectiveness of antidiabetic drugs are Type 2 diabetes risk genes making matters worse. Here, we shed light on these interindividual genetic differences.
2型糖尿病在全球的患病率仍在上升。抗糖尿病药物被广泛开给2型糖尿病患者。大多数患者从二甲双胍开始用药,该药大多耐受性良好。然而,很大一部分患者未能实现血糖控制。二甲双胍以及大多数其他抗糖尿病药物的有效性除其他因素外还取决于个体间的基因差异,而目前在2型糖尿病治疗中这些差异被忽视了。有趣的是,许多影响抗糖尿病药物有效性的基因也是2型糖尿病风险基因,这使得情况更糟。在此,我们揭示这些个体间的基因差异。